DHA Analog Polymer Formulations for Sustained Retinal and Inner Ear Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery methods for sensory organs like the retina and inner ear face challenges due to the blood-retina-barrier and blood-inner ear-barrier, requiring high doses for effective target concentration, which can lead to adverse events and inconsistent drug delivery.
Innovation Solution
Formulations of compounds in specific structures (Formula I, II, III, or IV) with crosslinked polymers like PEG, PLC, PGA, and PLGA, allowing for sustained release through injection, targeting the retina or inner ear.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high doses of drug are administered systemically to overcome the blood-retina-barrier and blood-inner ear-barrier, then effective drug concentrations in the target organ can be achieved, but adverse events increase and drug delivery consistency deteriorates
Solution Approach 1:
The patent introduces a barrier-penetrating peptide (BPP) as an intermediary carrier that facilitates drug transport across the blood-retina-barrier and blood-inner ear-barrier. The BPP conjugate acts as a mediator between the systemic circulation and the protected sensory organs, enabling effective drug delivery at lower doses without the adverse events associated with high-dose systemic administration
Solution Approach 2:
The patent modifies the drug's properties by conjugating it with a barrier-penetrating peptide, changing its ability to interact with and traverse the blood-retina-barrier and blood-inner ear-barrier. This parameter change in the drug's molecular structure enables selective penetration of the barriers while maintaining therapeutic efficacy at lower concentrations
2Object-affected harmful factors
If formulated drug is locally delivered by injection, then adverse events are reduced, but repeated injections are required which are clinically impractical
Solution Approach 1:
The patent creates a sustained-release formulation where the drug-BPP conjugate is embedded in a biodegradable polymer matrix that continuously releases the drug over an extended period. This continuous release mechanism eliminates the need for repeated injections while maintaining therapeutic drug levels at the target site, resolving the contradiction between reducing adverse events and avoiding frequent administration
Solution Approach 2:
The patent employs a pre-formulated injectable composition that is prepared in advance with controlled release properties. The drug is pre-conjugated with the barrier-penetrating peptide and embedded in the polymer matrix before injection, enabling sustained release action to begin immediately upon administration and continue over time without requiring additional interventions
3Ease of operation
If systemic drug administration is used, then ease of administration is improved, but drug delivery consistency to the target organ deteriorates due to barrier penetration variability
Solution Approach 1:
The barrier-penetrating peptide serves as a reliable intermediary that consistently facilitates drug transport across the blood-retina-barrier and blood-inner ear-barrier. This mediator ensures uniform and predictable drug delivery to the target organs while maintaining the simplicity of systemic administration, resolving the contradiction between ease of administration and delivery consistency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves controlled and sustained drug release to sensory organs, overcoming barriers and ensuring effective therapeutic concentrations without repeated injections.
Implementation Method 1
Formulations need to be identified that following injection of drug product will allow for sustained release of drug over a longer period of time
Implementation Method 2
deliver a therapeutically effective amount of a compound... over a defined period of time
Data Source
AI summary
The present invention relates to pharmaceutical compositions of docosahexaenoic acid (DHA) analogs for treating hearing and ocular disorders.